Prodrugs

Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability

Volumn 40, Issue , 2009, Pages 559-570

  Testa, Bernard ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

5 fluorouracil; Bioprecursos; Pharmaceutical objectives; Pharmacodynamic; Pharmacokinetic

Indexed keywords

PHARMACOKINETICS;

5-FLUOROURACIL; BIOPRECURSOS; PRODRUGS;

PHARMACODYNAMICS;

EID: 85017417458     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527623860.ch20     Document Type: Chapter

References (45)

1. Testa, B. (2007) Prodrug objectives and design, in ADME-Tox Approaches, Vol. 5 (eds B. Testa and H. van de Waterbeemd), in Comprehensive Medicinal Chemistry II (series eds J.B. Taylor and D.J. Triggle), Elsevier, Oxford, UK, pp. 1009-1041.
2. Testa, B. (2004) Prodrug research: futile or fertile? Biochemical Pharmacology, 68, 2097-2106.
3. Ettmayer, P., Amidon, G., Clement, B. and Testa, B. (2004) Lessons learned from marketed and investigational prodrugs. Journal of Medicinal Chemistry, 47, 2393-2404.
4. Testa, B. and Mayer, J.M. (2003) Hydrolysis in Drug and Prodrug Metabolism Chemistry, Biochemistry and Enzymology, Wiley-VHCA, Zurich.
5. Beaumont, K., Webster, R., Gardner, I. and Dack, K. (2003) Designofesterprodrugsto enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Current Drug Metabolism, 4, 461-485.
6. Testa, B. and Soine, W. (2003) Principles of drug metabolism, in Burgefs Medicinal Chemistry and Drug Discovery, Vol. 2, 6th edn (ed. D.J. Abraham), Wiley Interscience, Hoboken, NJ, pp. 431-498.
7. Testa, B. and Mayer, J.M. (2001) Concepts in prodrug design to overcome pharmacokinetic problems, in Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical and Computational Strategies (eds B. Testa, H. van de Waterbeemd, G. Folkers and R. Guy), Wiley-VHCA, Zurich, pp. 85-95.
8. Wang, W., Jiang, J., Ballard, C.E. and Wang, B. (1999) Prodrug approaches in the improved delivery of peptide drugs. Current Pharmaceutical Design, 5, 265-287.
9. Lee, H.J., You, Z., Ko, D.H. and McLean, H.M. (1998) Recent advances in prodrugs and antedrugs. Current Opinion in Drug Discovery & Development, 1, 235-244.
10. Bradley, D.A. (1996) Prodrugs for improved CNS delivery. Advanced Drug Delivery Reviews, 19, 171-202.
11. Testa, B. and Caldwell, J. (1996) Prodrugs revisited the "ad hoc" approach as a complement to ligand design. Medicinal Research Reviews, 16, 233-241.
12. Waller, D.G. and George, C.F. (1989) Prodrugs. British Journal of Clinical Pharmacology, 28, 497-507.
13. Stella, V.J., Charman, W.N.A. and Naringrekar, V.H. (1985) Prodrugs do they have advantages in clinical practice? Drugs, 29, 455-473.
14. Wermuth, C.G. (1984) Designing prodrugs and bioprecursors, in Drug Design: Fact or Fantasy? (eds G. Jolles and K.R.H. Woolridge), Academic Press, London, pp. 47-72.
15. Harper, N.J. (1962) Drug latentiation, in Progress in Drug Research, Vol. 4 (eds E. Jucker), Birkhauser, Basel, pp. 221-294.
16. Albert, A. (1958) Chemical aspects of selective toxicity. Nature, 182, 421-422.
17. Bodor, N. and Buchwald, P. (2000) Soft drug design: general principles and recent applications. Medicinal Research Reviews, 20, 58-101.
18. Bodor, N. (1984) Novel approaches to the design of safer drugs: soft drugs and site specific chemical delivery systems, in Advances in Drug Research, Vol. 13 (ed. B. Testa), Academic Press, London, pp. 255-331.
19. Benfield, P. and Sorkin, E.M. (1987) Esmolol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs, 33, 392-412.
20. Heimbach, T., Oh, D.M., Li, L.Y., Rodriguez-Hornedo, N., Garcia, G. and Fleisher, D. (2003) Enzyme-mediated precipitation of parent drug from their phosphate prodrugs. International Journal of Pharmaceutics, 26, 81-92.
21. Heimbach, T., Oh, D.M., Li, L.Y., Forsberg, M., Savolainen, J., Leppanen, J., Matsunaga, Y., Flynn, G. and Fleisher, D. (2003) Absorption rate limit considerations for oral phosphate prodrugs. Pharmaceutical Research, 20, 848-856.
22. Juntunen, J., Vepsalainen, J., Niemi, R., Laine, K. and Jarvinen, T. (2003) Synthesis, in vitro evaluation, and intraocular pressure effects ofwater-soluble prodrugs ofendocannabinoid noladin ether. Journal of Medicinal Chemistry, 46, 5083-5086.
23. Juntunen, J., Jaarvinen, T. and Niemi, R. (2005) In-vitro corneal permeation of cannabinoids and their water-soluble phosphate ester prodrugs. Journal of Pharmacy and Pharmacology, 57, 1153-1157.
24. Amidon, G.L., Lennernas, H., Shah, V.P. and Crison, J.R. (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12, 413-420.
25. Oxford, J.S. and Lambkin, R. (1998) Targeting influenza virus neuraminidase a new strategy for antiviral therapy. Drug Discovery Today, 3, 448-456.
26. Lew, W., Chen, X. and Kim, C.U. (2000) Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Current Medicinal Chemistry, 7, 663-672.
27. Svensson, L.A. and Tunek, A. (1988) The design and bioactivation of presystematically stable prodrugs. Drug Metabolism Reviews, 19, 165-194.
28. Persson, G., Pahlm, O. and Gnosspelius, Y. (1995) Oral bambuterol versus terbutaline in patients with asthma. Current Therapeutic Research, 56, 457-465.
29. Tsukamoto, Y., Kato, Y., Ura, M., Horii, I., Ishitsuka, H., Kusuhara, K. and Sugiyama, Y. (2001) A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor selective accumulation of 5-FU. Pharmaceutical Research, 18, 1190-1202.
30. Hwang, J.J. and Marshall, J.L. (2002) Capecitabine: fulfilling the promise of oral chemotherapy. Expert Opinion on Pharmacotherapy, 3, 733-743.
31. Savi, P., Pereillo, J.M., Uzabiaga, M.F., Combalbert, J., Picard, C., Maffrand, J.P., Pascal, M. and Herbert, J.M. (2000) Identification and biological activity of the active metabolite of clopidogrel. Thrombosis and Haemostasis, 84, 891-896.
32. Clarke, T.A. and Waskell, L.A. (2003) The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 31, 53-59.
33. Richter, T., Murdter, T.E., Heinkele, G., Pleiss, J., Tatzel, S., Schwab, M., Eichelbaum, M. and Zanger, U.M. (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. Journal of Pharmacology and Experimental Therapeutics, 308, 189-197.
34. Denny, W.A. (2005) Hypoxia-activated anticancer drugs. Expert Opinion on Therapeutic Patents, 15, 635-646.
35. Denny, W.A. (2003) Synthetic DNA targeted chemotherapeutic agents and related tumor-activated prodrugs, in Burger's Medicinal Chemistry and Drug Discovery, Vol. 5, 6th edn (ed. D.J. Abraham), Wiley-Interscience, Hoboken, NJ, pp. 51-105.
36. Dubowchik, G.M. and Walker, M.A. (1999) Receptor-mediated and enzyme dependent targeting of cytotoxic anticancer drugs. Pharmacology & Therapeutics, 83, 67-123.
37. Riley, R.J. and Workman, P. (1992) Enzymology ofthe reduction ofthe potent benzotriazine-di-N-oxide hypoxic cell cytotoxin SR4233 (WIN 59075) by NAD(P) H: (quinone acceptor) oxidoreductase (EC 1.6.99.2) purified from Walker 256 rat tumour cells. Biochemical Pharmacology, 43, 167-174.
38. Anderson, R.F., Shinde, S.S., Hay, M.P., Gamage, S.A. and Denny, W.A. (2003) Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. Journal ofthe American Chemical Society, 125, 748-756.
39. Veronese, F.M. and Pasut, G. (2007) Drug-polymer conjugates, in ADME-Tox Approaches, Vol. 5 (eds B. Testa and H. van de Waterbeemd), in Comprehensive Medicinal Chemistry II (series eds J.B. Taylor and D.J. Triggle), Elsevier, Oxford, UK, pp. 1043-1068.
40. Niculescu-Duvaz, I., Friedlos, F., Niculescu-Duvaz, D., Davies, L. and Springer, C.J. (1999) Prodrugs for antibody and gene-directed enzyme prodrug therapies (ADEPTand GDEPT). Anti-Cancer Drug Design, 14, 517-538.
41. Cassidy, J. (2000) Polymer-directed enzyme prodrug therapy. Drug News & Perspectives, 13, 477-480.
42. Springer, C.J. and Niculescu-Duvaz, I. (2000) Prodrug-activating systems in suicide gene therapy. The Journal ofClinical Investigation, 105, 1161-1167.
43. HariKrishna, D. Raghu Ram Rao, A. and Krishna, D.R. (2003) Selective activation of anthracycline prodrugs for use in conjunction with ADEPT. Drug News & Perspectives, 16, 309-318.
44. Davies, L.C., Friedlos, F., Hedley, D., Martin, J., Ogilvie, L.M., Scanlon, I.J. and Springer, C.J. (2005) Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy. Journal ofMedicinal Chemistry, 48, 5321-5328.
45. Testa, B. and Mayer, J.M. (1998) Design of intramolecularly activated prodrugs. Drug Metabolism Reviews, 30, 787-807.